Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight Review
  • Published:

The use of novel agents in the treatment of relapsed and refractory multiple myeloma

Leukemia volume 23, pages 2222–2232 (2009)Cite this article

Abstract

Although outcomes for patients with multiple myeloma (MM) have improved over the past decade, the disease remains incurable and even patients who respond well to induction therapy ultimately relapse and require additional treatment. Conventional chemotherapy and high-dose therapy with stem cell transplantation (SCT) have historically been utilized in the management of relapsed MM, but in recent years the immunomodulatory drugs (IMiDs) thalidomide and lenalidomide, as well as the proteasome inhibitor bortezomib, have assumed a primary role in this setting. This review focuses on the role of thalidomide, lenalidomide and bortezomib in relapsed and refractory MM, with additional discussion dedicated to emerging drugs in relapsed MM that may prove beneficial to patients with this disease.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Alexanian R, Barlogie B, Dixon D . High dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1986; 105: 8–11.

    CAS  PubMed  Google Scholar 

  2. Gertz MA, Garton JP, Greipp PR, Witzig TE, Kyle RA . A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma. Leukemia 1995; 9: 2115–2118.

    CAS  PubMed  Google Scholar 

  3. Barlogie B, Smith L, Alexanian R . Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310: 1353–1356.

    CAS  PubMed  Google Scholar 

  4. Anderson H, Scarffe JH, Ranson M, Young R, Wieringa GS, Morgenstern GR et al. VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer 1995; 71: 326–330.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Gertz MA, Kalish LA, Kyle RA, Hahn RG, Tormey DC, Oken MM . Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study. Am J Clin Oncol 1995; 18: 475–480.

    CAS  PubMed  Google Scholar 

  6. Lokhorst HM, Meuwissen OJ, Bast EJ, Dekker AW . VAD chemotherapy for refractory multiple myeloma. Br J Haematol 1989; 71: 25–30.

    CAS  PubMed  Google Scholar 

  7. Phillips JK, Sherlaw-Johnson C, Pearce R, Davies JM, Reilly JT, Newland AC et al. A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma. Leuk Lymphoma 1995; 17: 465–472.

    CAS  PubMed  Google Scholar 

  8. Durie BGM, Dixon DO, Carter S, Stephens R, Rivkin S, Bonnet J et al. Improved survival duration with combination chemotherapy induction for multiple myeloma: A Southwest Oncology Group Study. J Clin Oncol 1986; 4: 1227–1237.

    CAS  PubMed  Google Scholar 

  9. Giles FJ, Wickham NR, Rapoport BL, Somlo G, Lim SW, Shan J et al. Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: an International Oncology Study Group (IOSG) phase II protocol. Am J Hematol 2000; 63: 125–130.

    CAS  PubMed  Google Scholar 

  10. Barlogie B, Hall R, Zander A, Dicke K, Alexanian R . High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986; 67: 1298–1301.

    CAS  PubMed  Google Scholar 

  11. Barlogie B, Alexanian R, Dicke KA, Zagars G, Spitzer G, Jagannath S et al. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987; 70: 869–872.

    CAS  PubMed  Google Scholar 

  12. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115–1123.

    CAS  PubMed  Google Scholar 

  13. D'Amato RJ, Loughman MS, Flynn E, Folkman J . Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082–4085.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994; 87: 503–508.

    CAS  PubMed  Google Scholar 

  15. Vacca A, Di Loreto M, Ribatti D, Di Stefano R, Gadaleta-Caldarola G, Iodice G et al. Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44. Am J Hematol 1995; 50: 9–14.

    CAS  PubMed  Google Scholar 

  16. Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG, Anderson KC . The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer 2006; 42: 1564–1573.

    CAS  PubMed  Google Scholar 

  17. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai Y-T et al. Thalidomide and its analogues overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943–2950.

    CAS  PubMed  Google Scholar 

  18. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210–216.

    CAS  PubMed  Google Scholar 

  19. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002; 99: 4525–4530.

    CAS  PubMed  Google Scholar 

  20. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–1571.

    CAS  PubMed  Google Scholar 

  21. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492–494.

    CAS  PubMed  Google Scholar 

  22. van Rhee F, Dhodapkar M, Shaughnessy Jr JD, Anaissie E, Siegel D, Hoering A et al. First thalidomide clinical trial in multiple myeloma: a decade. Blood 2008; 112: 1035–1038.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Hus M, Dmoszynska A, Soroka-Wojtaszko M, Jawniak D, Legiec W, Ciepnuch H et al. Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica 2001; 86: 404–408.

    CAS  PubMed  Google Scholar 

  24. Mileshkin L, Biagi JJ, Mitchell P, Underhill C, Grigg A, Bell R et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 2003; 102: 69–77.

    CAS  PubMed  Google Scholar 

  25. Neben K, Moehler T, Benner A, Kraemer A, Egerer G, Ho AD et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 2002; 8: 3377–3382.

    CAS  PubMed  Google Scholar 

  26. Schey SA, Cavenagh J, Johnson R, Child JA, Oakervee H, Jones RW . An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. Leuk Res 2003; 27: 909–914.

    CAS  PubMed  Google Scholar 

  27. Tosi P, Zamagni E, Cellini C, Ronconi S, Patriarca F, Ballerini F et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica 2002; 87: 408–414.

    CAS  PubMed  Google Scholar 

  28. Waage A, Gimsing P, Juliusson G, Turesson I, Gulbrandsen N, Eriksson T et al. Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. Br J Haematol 2004; 125: 149–155.

    CAS  PubMed  Google Scholar 

  29. Wu KL, Helgason HH, van der Holt B, Wijermans PW, Lokhorst HM, Smit WM et al. Analysis of efficacy and toxicity of thalidomide in 122 patients with multiple myeloma: response of soft-tissue plasmacytomas. Leukemia 2005; 19: 143–145.

    CAS  PubMed  Google Scholar 

  30. Yakoub-Agha I, Attal M, Dumontet C, Delannoy V, Moreau P, Berthou C et al. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myelome (IFM). Hematol J 2002; 3: 185–192.

    CAS  PubMed  Google Scholar 

  31. Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, von Lilienfeld-Toal M et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006; 132: 584–593.

    CAS  PubMed  Google Scholar 

  32. Yakoub-Agha I, Doyen C, Hulin C, Marit G, Voillat L, Grosbois B et al. A multicenter prospective randomized study testing non-inferiority of thalidomide 10 mg/day as compared with 400 mg/day in patients with refractory/relapsed multiple myeloma: results of the final analysis of the IFM 01-02 study. Abstract 7520. In: American Society of Clinical Oncology, Annual Meeting 2006.

  33. Dimopoulos MA, Zervas K, Kouvatseas G, Galani E, Grigoraki V, Kiamouris C et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001; 12: 991–995.

    CAS  PubMed  Google Scholar 

  34. Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R . Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003; 121: 768–771.

    CAS  PubMed  Google Scholar 

  35. Palumbo A, Giaccone L, Bertola A, Pregno P, Bringhen S, Rus C et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 2001; 86: 399–403.

    CAS  PubMed  Google Scholar 

  36. Palumbo A, Falco P, Ambrosini MT, Petrucci MT, Musto P, Caravita T et al. Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant. Eur J Haematol 2005; 75: 391–395.

    CAS  PubMed  Google Scholar 

  37. Lee CK, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003; 21: 2732–2739.

    CAS  PubMed  Google Scholar 

  38. Offidani M, Corvatta L, Marconi M, Visani G, Alesiani F, Brunori M et al. Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study. Haematologica 2006; 91: 133–136.

    CAS  PubMed  Google Scholar 

  39. Dimopoulos MA, Hamilos G, Zomas A, Gika D, Efstathiou E, Grigoraki V et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J 2004; 5: 112–117.

    CAS  PubMed  Google Scholar 

  40. Garcia-Sanz R, Gonzalez-Porras JR, Hernandez JM, Polo-Zarzuela M, Sureda A, Barrenetxea C et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 2004; 18: 856–863.

    CAS  PubMed  Google Scholar 

  41. Kyriakou C, Thomson K, D'Sa S, Flory A, Hanslip J, Goldstone AH et al. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br J Haematol 2005; 129: 763–770.

    CAS  PubMed  Google Scholar 

  42. Palumbo A, Facon T, Sonneveld P, Blade J, Offidani M, Gay F et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 2008; 111: 3968–3977.

    CAS  PubMed  Google Scholar 

  43. Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM . Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006; 24: 4507–4514.

    CAS  PubMed  Google Scholar 

  44. Dimopoulos MA, Eleutherakis-Papaiakovou V . Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 2004; 117: 508–515.

    CAS  PubMed  Google Scholar 

  45. LeBlanc R, Hideshima T, Catley LP, Shringarpure R, Burger R, Mitsiades N et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004; 103: 1787–1790.

    CAS  PubMed  Google Scholar 

  46. Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu L, Tang Y et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 2005; 69: 56–63.

    CAS  PubMed  Google Scholar 

  47. Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006; 108: 618–621.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063–3067.

    CAS  PubMed  Google Scholar 

  49. Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108: 3458–3464.

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133–2142.

    CAS  PubMed  Google Scholar 

  51. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123–2132.

    CAS  PubMed  Google Scholar 

  52. Morgan GJ, Schey SA, Wu P, Srikanth M, Phekoo KJ, Jenner M et al. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol 2007; 137: 268–269.

    PubMed  Google Scholar 

  53. Knop S, Gerecke C, Liebisch P, Topp MS, Platzbecker U, Sezer O et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 2009; 113: 4137–4143.

    CAS  PubMed  Google Scholar 

  54. Sviggum HP, Davis MD, Rajkumar SV, Dispenzieri A . Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Arch Dermatol 2006; 142: 1298–1302.

    CAS  PubMed  Google Scholar 

  55. Castaneda CP, Zeldis JB, Freeman J, Quigley C, Brandenburg NA, Bwire R . RevAssist: a comprehensive risk minimization programme for preventing fetal exposure to lenalidomide. Drug Saf 2008; 31: 743–752.

    CAS  PubMed  Google Scholar 

  56. Myung J, Kim KB, Crews CM . The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 2001; 21: 245–273.

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002; 99: 14374–14379.

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20: 4420–4427.

    CAS  PubMed  Google Scholar 

  59. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609–2617.

    CAS  PubMed  Google Scholar 

  60. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127: 165–172.

    CAS  PubMed  Google Scholar 

  61. Jagannath S, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007; 21: 151–157.

    CAS  PubMed  Google Scholar 

  62. Sagaster V, Ludwig H, Kaufmann H, Odelga V, Zojer N, Ackermann J et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 2007; 21: 164–168.

    CAS  PubMed  Google Scholar 

  63. Chang H, Trieu Y, Qi X, Xu W, Stewart KA, Reece D . Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res 2007; 31: 779–782.

    CAS  PubMed  Google Scholar 

  64. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 2005; 106: 2977–2981.

    CAS  PubMed  Google Scholar 

  65. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498.

    CAS  PubMed  Google Scholar 

  66. Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007; 110: 3557–3560.

    CAS  PubMed  Google Scholar 

  67. Mikhael JR, Belch AR, Prince HM, Lucio MN, Maiolino A, Corso A et al. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol 2009; 144: 169–175.

    CAS  PubMed  Google Scholar 

  68. Hideshima T, Richardson P, Chauhan D, Palombella V, Elliott P, Adams J et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071–3076.

    CAS  PubMed  Google Scholar 

  69. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377–2380.

    CAS  PubMed  Google Scholar 

  70. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003; 9: 1136–1144.

    CAS  PubMed  Google Scholar 

  71. Biehn SE, Moore DT, Voorhees PM, Garcia RA, Lehman MJ, Dees EC et al. Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. Ann Hematol 2007; 86: 211–216.

    CAS  PubMed  Google Scholar 

  72. Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105: 3058–3065.

    CAS  PubMed  Google Scholar 

  73. Orlowski RZ, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007; 25: 3892–3901.

    CAS  PubMed  Google Scholar 

  74. Palumbo A, Gay F, Bringhen S, Falcone A, Pescosta N, Callea V et al. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Ann Oncol 2008; 19: 1160–1165.

    CAS  PubMed  Google Scholar 

  75. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006; 24: 3113–3120.

    CAS  PubMed  Google Scholar 

  76. Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007; 110: 1042–1049.

    CAS  PubMed  Google Scholar 

  77. Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005; 106: 3777–3784.

    CAS  PubMed  PubMed Central  Google Scholar 

  78. Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 2008; 26: 4784–4790.

    CAS  PubMed  Google Scholar 

  79. Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007; 109: 2604–2606.

    CAS  PubMed  Google Scholar 

  80. Dimopoulos MA, Kastritis E, Rosinol L, Blade J, Ludwig H . Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 2008; 22: 1485–1493.

    CAS  PubMed  Google Scholar 

  81. Zappasodi P, Dore R, Castagnola C, Astori C, Varettoni M, Mangiacavalli S et al. Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma. J Clin Oncol 2007; 25: 3380–3381.

    PubMed  Google Scholar 

  82. Miyakoshi S, Kami M, Yuji K, Matsumura T, Takatoku M, Sasaki M et al. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 2006; 107: 3492–3494.

    CAS  PubMed  Google Scholar 

  83. Duek A, Feldberg E, Haran M, Berrebi A . Pulmonary fibrosis in a myeloma patient on bortezomib treatment. A new severe adverse effect of a new drug. Am J Hematol 2007; 82: 502–503.

    PubMed  Google Scholar 

  84. Pineda-Roman M, Zangari M, van Rhee F, Anaissie E, Szymonifka J, Hoering A et al. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia 2008; 22: 1419–1427.

    CAS  PubMed  PubMed Central  Google Scholar 

  85. Richardson PG, Jagannath S, Avigan DE, Munshi NC, Ghobrial I, Doss D et al. Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): final results of a multicenter phase 1 trial. Abstract 405. In: American Society of Hematology Annual Meeting; 2006.

  86. Richardson P, Jagannath S, Jakubowiak A, Lonial S, Raje N, Alsina M et al. Lenalidomide, bortezomib, and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (MM): encouraging response rates and tolerability with correlation of outcome and adverse cytogenetics in a phase II study. Abstract 1742. In: American Society of Hematology Annual Meeting; 2008.

  87. Palumbo A, Falco P, Sanpaolo G, Falcone A, Ferderico V, Canepa L et al. Combination of lenalidomide, melphalan, prednisone and thalidomide (RMPT) in relapsed/refractory multiple myeloma: results of a multicenter phase II clinical trial. Abstract 868. In: American Society of Hematology Annual Meeting 2008.

  88. Dawson MA, Opat SS, Taouk Y, Donovan M, Zammit M, Monaghan K et al. Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma. Clin Cancer Res 2009; 15: 714–722.

    CAS  PubMed  Google Scholar 

  89. von Metzler I, Krebbel H, Hecht M, Manz RA, Fleissner C, Mieth M et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 2007; 21: 2025–2034.

    CAS  PubMed  Google Scholar 

  90. Mukherjee S, Raje N, Schoonmaker JA, Liu JC, Hideshima T, Wein MN et al. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 2008; 118: 491–504.

    CAS  PubMed  PubMed Central  Google Scholar 

  91. Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005; 8: 407–419.

    CAS  PubMed  Google Scholar 

  92. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007; 110: 3281–3290.

    CAS  PubMed  PubMed Central  Google Scholar 

  93. Vij R, Stewart AK, Somlo G, Jakubowiak A, Reiman T, Trudel S et al. Initial results of PX-171-004, an open-label, single-arm, Phase II study of carfilzomib (CFZ) in patients with relapsed myeloma (MM). Blood 2008; 102: 320.

    Google Scholar 

  94. Jagannath S, Vij R, Stewart AK, Somlo G, Jakubowiak A, Reiman T et al. Initial results of PX-171-003, an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients with relapsed and refractory multiple myeloma (MM). Blood 2008; 102: 319.

    Google Scholar 

  95. Richardson P, Hofmeister CC, Zimmerman TM, Chanan-Khan AA, Spear MA, Palladino MA et al. Phase I clinical trial of NPI-0052, a novel proteasome inhibitor in patients with multiple myeloma. Abstract 2770. In: American Society of Hematology Annual Meeting 2008.

  96. Schey SA, Fields P, Bartlett JB, Clarke IA, Ashan G, Knight RD et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004; 22: 3269–3276.

    CAS  PubMed  Google Scholar 

  97. Streetly M, Hunt BJ, Parmar K, Jones R, Zeldis J, Schey S . Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (CC-4047) and their relationship with venous thrombosis. Eur J Haematol 2005; 74: 293–296.

    CAS  PubMed  Google Scholar 

  98. Lacy MQ, Hayman SR, Gertz MA, Allred JB, Mandrekar SJ, Dispenzieri A et al. Pomalidomide (CC4047) plus low-dose dexamethasone (Pom/dex) is highly effective therapy in relapsed multiple myeloma. Abstract 866. In: American Society of Hematology Annual Meeting; 2008.

  99. Gallinari P, Di Marco S, Jones P, Pallaoro M, Steinkuhler C . HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res 2007; 17: 195–211.

    CAS  PubMed  Google Scholar 

  100. Roth SY, Denu JM, Allis CD . Histone acetyltransferases. Annu Rev Biochem 2001; 70: 81–120.

    CAS  PubMed  Google Scholar 

  101. Marks PA, Miller T, Richon VM . Histone deacetylases. Curr Opin Pharmacol 2003; 3: 344–351.

    CAS  PubMed  Google Scholar 

  102. Minucci S, Pelicci PG . Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6: 38–51.

    CAS  PubMed  Google Scholar 

  103. Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003; 101: 4055–4062.

    CAS  PubMed  Google Scholar 

  104. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 2004; 101: 540–545.

    CAS  PubMed  Google Scholar 

  105. Weber D, Badros AZ, Jagannath S, Siegel D, Richon V, Rizvi S et al. Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: early clinical experience. Blood 2008; 102: 322.

    Google Scholar 

  106. Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006; 108: 3441–3449.

    CAS  PubMed  PubMed Central  Google Scholar 

  107. Khan SB, Maududi T, Barton K, Ayers J, Alkan S . Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br J Haematol 2004; 125: 156–161.

    CAS  PubMed  Google Scholar 

  108. Haggarty SJ, Koeller KM, Wong JC, Butcher RA, Schreiber SL . Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays. Chem Biol 2003; 10: 383–396.

    CAS  PubMed  Google Scholar 

  109. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL . Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 2003; 100: 4389–4394.

    CAS  PubMed  PubMed Central  Google Scholar 

  110. Hideshima H, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL et al. Small molecule inhibition of proteasome and aggresome function induces synergistic anti-tumor activity in multiple myeloma. Proc Natl Acad Sci USA 2005; 102: 8567–8572.

    CAS  PubMed  PubMed Central  Google Scholar 

  111. Tu Y, Gardner A, Lichtenstein A . The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res 2000; 60: 6763–6770.

    CAS  PubMed  Google Scholar 

  112. Hideshima T, Nakamura N, Chauhan D, Anderson KC . Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001; 20: 5991–6000.

    CAS  PubMed  Google Scholar 

  113. Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D et al. Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002; 21: 5673–5683.

    CAS  PubMed  Google Scholar 

  114. Pene F, Claessens YE, Muller O, Viguie F, Mayeux P, Dreyfus F et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 2002; 21: 6587–6597.

    CAS  PubMed  Google Scholar 

  115. Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006; 107: 4053–4062.

    CAS  PubMed  PubMed Central  Google Scholar 

  116. Richardson PG, Lonial S, Jakubowiak A, Krishnan A, Wolf J, Singhal S et al. Perifosine (KRX-0401)+low dose dexamethasone is active in patients with relapsed and refractory multiple myeloma (MM): perifosine MM investigator group phase II multicenter study update. Abstract PO-607. In: XIth International Myeloma Workshop 2007.

  117. Jakubowiak A, Richardson P, Zimmerman TM, Alsina M, Kaufman JL, Harvey C et al. Phase I results of perifosine (KRX0-0401) in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (MM). Abstract 3691. In: American Society of Hematology Annual Meeting; 2008.

  118. Richardson P, Wolf J, Jakubowiak A, Zonder J, Lonial S, Irwin DH et al. Phase I/II results of a multicenter trial of perifosine (KRX-0401)+bortezomib in patients with relapsed or relapsed/refractory multiple myeloma who were previously relapsed from or refractory to bortezomib. Blood 2008; 102: 321.

    Google Scholar 

  119. Drysdale MJ, Brough PA, Massey A, Jensen MR, Schoepfer J . Targeting Hsp90 for the treatment of cancer. Curr Opin Drug Discov Devel 2006; 9: 483–495.

    CAS  PubMed  Google Scholar 

  120. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, Davies FE et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006; 107: 1092–1100.

    CAS  PubMed  PubMed Central  Google Scholar 

  121. Duus J, Bahar HI, Venkataraman G, Ozpuyan F, Izban KF, Al-Masri H et al. Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma. Leuk Lymphoma 2006; 47: 1369–1378.

    CAS  PubMed  Google Scholar 

  122. Chatterjee M, Jain S, Stuhmer T, Andrulis M, Ungethum U, Kuban RJ et al. STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival. Blood 2007; 109: 720–728.

    CAS  PubMed  Google Scholar 

  123. Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, Anderson J et al. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma. Clin Cancer Res 2006; 12: 6826–6835.

    CAS  PubMed  Google Scholar 

  124. Davenport EL, Moore HE, Dunlop AS, Sharp SY, Workman P, Morgan GJ et al. Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood 2007; 110: 2641–2649.

    CAS  PubMed  Google Scholar 

  125. Richardson P, Chanan-Khan A, Lonial S, Krishnan A, Alsina M, Carroll M et al. A multicenter phase I clinical trial of tanespimycin (KOS-953)+bortezomib (BZ): encouraging activity and manageable toxicity in heavily pre-treated patients with relapsed refractory multiple myeloma (MM). Abstract 406. In: American Society of Hamatology Annual Meeting 2006.

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Harvard Medical School, Dana Farber Cancer Institute, Boston, MA, USA

    J P Laubach, C S Mitsiades, R L Schlossman, N C Munshi, I M Ghobrial, N Carreau, T Hideshima, K C Anderson & P G Richardson

  2. Department of Medical Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA

    A Mahindra

Authors
  1. J P Laubach
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Mahindra
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C S Mitsiades
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R L Schlossman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N C Munshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. I M Ghobrial
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N Carreau
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T Hideshima
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. K C Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. P G Richardson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J P Laubach.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Laubach, J., Mahindra, A., Mitsiades, C. et al. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia 23, 2222–2232 (2009). https://doi.org/10.1038/leu.2009.179

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2009.179

Keywords

This article is cited by

Search

Advanced search

Quick links